Harnessing the Spirit of Cooperation to Revolutionize Cancer Treatment
Harnessing the Spirit of Cooperation to Revolutionize Cancer Treatment
LEADING THE FUTURE OF CELL THERAPY WITH OUR AlloCAR T™ PLATFORM
INNOVATION
- Multiplex gene-engineering and gene-editing capabilities
- Proprietary lymphodepletion platform
- State-of-the-art manufacturing
- Opportunity for product optimization
PIPELINE
- CD19
- ALLO-501A – Phase 2
- BCMA
- ALLO-715 – Phase 1
- ALLO-605 – Phase 1
- CD70
- ALLO-316 – Phase 1
LEADERSHIP
- A highly experienced management team that includes key pioneers of CAR T cell products
- Approximately 350 employees singularly focused on the development of AlloCAR T™ products
- Allogene is proud to have approximately 50% of our senior leadership team and entire organization identify as female
WE DON’T JUST SEE THE FUTURE.
WE KNOW HOW TO GET THERE.
Our mission is to create and lead the next revolution in cancer treatment by delivering to patients the first allogeneic CAR T cell (AlloCAR T™) products for blood cancers and solid tumors
WHY ALLOGENEIC CELL PRODUCTS HAVE THE POTENTIAL TO LEAD THE REVOLUTION
ACCESS
- Potential to treat all
eligible patients - Repeat dosing, if needed
- No need for complex logistics
COST
- Scalable and efficient manufacturing
- Potential to treat 100+ patients from a single manufacturing run
- Lower ancillary costs of care
SPEED/RELIABILITY
- Off-the-shelf for on-demand treatment
- Less product variability, made from healthy T cells
OUR PARTNERS
